Abstracts tagged "Janus kinase (JAK)"

Abstract Number: 1525 • 2018 ACR/ARHP Annual Meeting
Effect of JAK-Inhibitor Versus Bdmards on Quality of Life in Rheumatoid Arthritis : A Meta Analysis of Randomized Controlled Trials
Mamadaly Boudhabhay¹, Thomas Barnetche² and Pascale Vergne-Salle³, ¹CHU de Limoges, Limoges, France, ²Rheumatology Department, FHU ACRONIM, Bordeaux University Hospital, Bordeaux, France, ³Rheumatology, CHU de Limoges, Limoges, France
Background/Purpose: Recent studies comparing JAK-inhibitors (Jak-i) and adalimumab seem to show a better efficacy of JAK-i on patient-reported outcomes in rheumatoid arthritis (RA). As there…
Abstract Number: 2565 • 2018 ACR/ARHP Annual Meeting
Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, up to 36 Months in Patients with Active Psoriatic Arthritis: Data from the Third Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study
Peter Nash¹, Laura C. Coates², Alan J. Kivitz³, Philip J. Mease⁴, Dafna D Gladman⁵, Jose A Covarrubias-Cobos⁶, Dona Fleishaker⁷, Cunshan Wang⁷, Elizabeth Kudlacz⁷, Sujatha Menon⁷, Lara Fallon⁸, Thijs Hendrikx⁹ and Keith S Kanik⁷, ¹University of Queensland, Brisbane, Australia, ²University of Oxford, Oxford, United Kingdom, ³Altoona Center for Clinical Research, Duncansville, PA, ⁴Swedish Medical Center and University of Washington, Seattle, WA, ⁵Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁶Unidad Reumatologica Las Americas S.C.P, Mérida, Yucatan, Mexico, ⁷Pfizer Inc, Groton, CT, ⁸Pfizer Canada, Montreal, QC, Canada, ⁹Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA). We report the safety, tolerability, and efficacy of tofacitinib in…
Abstract Number: 1530 • 2018 ACR/ARHP Annual Meeting
CRP Changes during Bacterial Infections in Baricitinib-Treated Patients with RA
Oliver Hendricks¹, Stavros Chrysidis², Jens Gerwien³, Chadi Saifan³, Francesco de Leonardis³, Pedro Lopez-Romero³, Jinglin Zhong⁴, Kevin Winthrop⁵ and Josef S. Smolen⁶, ¹King Chr.Xs Rheumatology Hospital, Graasten, Denmark, ²Rheumatology Department Sydvestjysk Sygehus, Esbjerg, Denmark, ³Eli Lilly and Company, Indianapolis, IN, ⁴Quintiles, Rockville, MD, ⁵Oregon Health Sciences University, Portland, OR, ⁶Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria
Background/Purpose: Baricitinib (BARI) is a selective inhibitor of Janus kinase 1/2, modulating responses to inflammatory cytokines, e.g. IL-6 or IFNs1. During acute inflammation, including those…
Abstract Number: 2815 • 2018 ACR/ARHP Annual Meeting
Cardiovascular Safety – Update from up to 6 Years of Treatment with Baricitinib in Rheumatoid Arthritis Clinical Trials
Michael Weinblatt¹, Peter C. Taylor², Gerd R. Burmester³, Chadi Saifan⁴, Chad D. Walls⁴, Maher Issa⁴, Terence P. Rooney⁴ and Tsutomu Takeuchi⁵, ¹Brigham and Women’s Hospital, Boston, MA, ²Botnar Research Centre, Univ of Oxford, Oxford, United Kingdom, ³Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Baricitinib (BARI), a selective inhibitor of Janus kinases, is approved in >40 countries for the treatment of active rheumatoid arthritis (RA) in adults. Patients…
Abstract Number: 224 • 2018 ACR/ARHP Annual Meeting
Risk of Venous Thrombotic Events in Rheumatoid Arthritis Patients Initiating Tofacitinib or Adalimumab
Huifeng Yun, Fenglong Xie, Lang Chen and Jeffrey R. Curtis, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Recent concern has been raised for a risk for venous thromboembolism (VTE) associated with janus kinase inhibitors among patients with RA who are already…
Abstract Number: 1536 • 2018 ACR/ARHP Annual Meeting
Mean Platelet Volume Changes with Baricitinib Indicate Reduced New Platelet Production in Baricitinib-Treated Rheumatoid Arthritis Patients
Jon T. Giles¹, Michael T. Nurmohamed², Henry M. Rinder³, Venkatesh Krishnan⁴, Brenda J. Crowe⁴, Chadi Saifan⁴ and Thomas Dörner⁵, ¹Columbia University, New York, NY, ²VU University Medical Center, Amsterdam, Netherlands, ³Yale University School of Medicine, New Haven, CT, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Charité Universitätsmedizin Berlin and Deutsches Rheuma-Forschungszentrum (DRFZ), Berlin, Germany
Background/Purpose: Transient increases in circulating platelets were observed in patients with RA treated with baricitinib, an oral selective Janus kinase 1/2 inhibitor, approved for the…
Abstract Number: 525 • 2018 ACR/ARHP Annual Meeting
Low Interstitial Lung Disease Event Rate in Patients with Rheumatoid Arthritis: Pooled Post Hoc Analysis of Data from the Tofacitinib Clinical Development Program
Gustavo Citera¹, Eduardo Mysler², Hugo Madariaga³, Mario H Cardiel⁴, Oswaldo Castañeda⁵, Aryeh Fischer⁶, Pascal Richette⁷, Sandra Chartrand⁸, Jin Kyun Park⁹, Sander Strengholt¹⁰, Jose L Rivas¹¹, Amit Thorat¹², Tanya Girard¹³, Kenneth Kwok¹⁴, Lisy Wang¹⁵ and Dario Ponce de Leon¹⁶, ¹Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ²Organización Médica de Investigación, Buenos Aires, Argentina, ³Clínica del Sur, Arequipa, Peru, ⁴Centro de Investigación Clínica de Morelia, Morelia, Mexico, ⁵Clínica Anglo Americana, Lima, Peru, ⁶Department of Medicine, University of Colorado, Denver, CO, ⁷Lariboisière Hospital, Lariboisière, University of Paris 7, Paris, France, ⁸Department of Medicine, Hôpital Maisonneuve-Rosemont affiliated to Université de Montréal, Montréal, QC, Canada, ⁹Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South), ¹⁰Pfizer Inc, Capelle aan den IJssel, Netherlands, ¹¹Pfizer SLU, Madrid, Spain, ¹²Pfizer Ltd, Mumbai, India, ¹³Pfizer Inc, Montréal, QC, Canada, ¹⁴Pfizer Inc, New York, NY, ¹⁵Pfizer Inc, Groton, CT, ¹⁶Pfizer Inc, Lima, Peru
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Interstitial lung disease (ILD) is a common extra-articular manifestation of RA,1 and…
Abstract Number: 1586 • 2018 ACR/ARHP Annual Meeting
Expression of JAK Proteins and Autophagy Markers in Sjögren’s Syndrome Patients
María-José Barrera^1,2, Sergio Aguilera³, Isabel Castro², Patricia Carvajal², Sergio González⁴, Claudio Molina¹, Ulises Urzua² and María-Julieta González², ¹Facultad de Odontología, Universidad San Sebastián, Santiago, Chile, ²Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Santiago, Chile, ³Reumatologia, Clinica Indisa, Santiago, Chile, ⁴Facultad de Odontología, Universidad Mayor, Santiago, Chile
Background/Purpose: Sjögren’s syndrome (SS) is an autoimmune epitheliitis that mainly affects the salivary and lachrymal glands. The glandular hypofunction has been associated to loss of…
Abstract Number: 557 • 2018 ACR/ARHP Annual Meeting
The Impact of Comedication with Conventional Synthetic Dmards on Drug Retention and Clinical Effectiveness of Tofacitinib, Anti–Tumor Necrosis Factor Therapy and Biologics with an Alternative Mode of Action in Patients with Rheumatoid Arthritis. a Cohort Study
Axel Finckh¹, Christophe Tellenbach², Almut Scherer², Burkhard Moeller³, Adrian Ciurea⁴, Ines von Mühlenen⁵, Cem Gabay⁶, Diego Kyburz⁷, Ruediger Mueller⁸, Paul Hasler⁹ and Pascal Zufferey¹⁰, ¹University Hospital of Geneva, Geneva, Switzerland, ²SCQM Foundation, Zurich, Switzerland, ³Rheumatology, Immunology and Allergology, Inselspital, University Hospital of Bern, Bern, Switzerland, ⁴Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁵Rheuma-Basel, Basel, Switzerland, ⁶University Hospitals of Geneva, Geneva, Switzerland, ⁷Rheumatology, University Hospital Basel, Basel, Switzerland, ⁸Division of Rheumatology, Kantonsspital St Gallen, St. Gallen, Switzerland, ⁹Kantonsspital Aarau AG, Aarau, Switzerland, ¹⁰Department of Rheumatology, University Hospital Lausanne, Lausanne, Switzerland
Background/Purpose: Co-medication with conventional synthetic DMARDs (csDMARDs) is currently recommended with all targeted therapies (bDMARDs and tsDMARDs) for the management of rheumatoid arthritis (RA). However,…
Abstract Number: 1894 • 2018 ACR/ARHP Annual Meeting
Baricitinib-Associated Changes in Type l Interferon Gene Signature during a 24-Week Phase-2 Clinical SLE Trial
Thomas Dörner¹, Yoshiya Tanaka², Michelle Petri³, Josef S. Smolen⁴, Ernst R. Dow⁵, Richard E. Higgs⁵, Robert J. Benschop⁵, Adam Abel⁵, Maria E. Silk⁵, Stephanie de Bono⁵ and Robert W. Hoffman⁵, ¹Charité Universitätsmedizin Berlin and Deutsches Rheuma-Forschungszentrum (DRFZ), Berlin, Germany, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ⁵Eli Lilly and Company, Indianapolis, IN
Background/Purpose: In the phase 2 study JAHH (NCT02708095), treatment with baricitinib (bari), an oral selective Janus kinase 1/2 inhibitor approved for the treatment of RA,…
Abstract Number: 10L • 2017 ACR/ARHP Annual Meeting
Upadacitinib (ABT-494) in Patients with Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Biological Dmards: A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study of a Selective JAK-1 Inhibitor
Mark C. Genovese¹, Roy Fleischmann², Bernard Combe³, Stephen Hall⁴, Ying Zhang⁵, Yijie Zhou⁵, Mohamed-Eslam F. Mohamed⁶, Sebastian Meerwein⁷ and Aileen L. Pangan⁵, ¹Stanford University Medical Center, Palo Alto, CA, ²University of Texas Southwestern Medical Center at Dallas, Dallas, TX, ³Rheumatology, CHU Lapeyronie and Montpellier University, Montpellier, France, ⁴Department of Medicine, Monash University, Cabrini Health and Emeritus Research, Malvern, Australia, ⁵AbbVie Inc., North Chicago, IL, ⁶Clinical Pharmacology and Pharmacometrics, AbbVie Inc., North Chicago, IL, ⁷AbbVie Deutschland GmbH & Co, Ludwigshafen, Germany

Background/Purpose: Upadacitinib (ABT-494, UPA), an oral, selective JAK-1 inhibitor was effective in 2 ph2 trials in rheumatoid arthritis (RA) pts with inadequate response (IR)/intolerance to…
Abstract Number: 16L • 2017 ACR/ARHP Annual Meeting
Incidence of Thromboembolic Events in the Tofacitinib Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis and Ulcerative Colitis Development Programs
Philip J Mease¹, Joel Kremer², Stanley Cohen³, Jeffrey R Curtis⁴, Christina Charles-Schoeman⁵, Edward V Loftus⁶, Jeffrey D Greenberg⁷, Niki Palmetto⁸, Keith S Kanik⁹, Daniela Graham⁹, Cunshan Wang⁹, Pinaki Biswas⁸, Gary Chan¹⁰, Ryan DeMasi¹⁰, Hernan Valdez⁸, Thijs Hendrikx¹⁰ and Thomas V Jones¹⁰, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY, ³Metroplex Clinical Research Center, Dallas, TX, ⁴University of Alabama, Birmingham, AL, ⁵University of California, Los Angeles, CA, ⁶Mayo Clinic, Rochester, MN, ⁷Corrona, LLC, Southborough, MA, ⁸Pfizer Inc, New York, NY, ⁹Pfizer Inc, Groton, CT, ¹⁰Pfizer Inc, Collegeville, PA

Background/Purpose: Tofacitinib is an oral Janus kinase (JAK) inhibitor that preferentially inhibits signaling by JAK3 and JAK1, with functional selectivity over JAK2. Potential increased risk…
Abstract Number: 504 • 2017 ACR/ARHP Annual Meeting
Monotherapy with Filgotinib, a JAK1-Selective Inhibitor, Reduces Disease-Related Biomarkers in Rheumatoid Arthritis Patients
Peter C. Taylor¹, René Galien², Annegret Van der Aa³, Corinne Jamoul³, Pille Harrison³, Chantal Tasset³, Yang Pan⁴, Lovely Goyal⁴, Wanying Li⁴ and Jacqueline Tarrant⁴, ¹Kennedy Institute of Rheumatology, London, United Kingdom, ²Galapagos SASU, Romainville, France, ³Galapagos NV, Mechelen, Belgium, ⁴Gilead Sciences, Foster City, CA
Background/Purpose: The JAK1 selective inhibitor filgotinib (GLPG0634, GS-6034) has been evaluated in a 24-week phase 2B study (DARWIN 2) as monotherapy in active rheumatoid arthritis…
Abstract Number: 1893 • 2017 ACR/ARHP Annual Meeting
Pharmacokinetics (PK), Pharmacodynamics (PD), and Proposed Dosing of Oral Janus Kinase (JAK)1 and JAK2 Inhibitor Baricitinib in Patients with IFN-Mediated Autoinflammatory Diseases (AIDs)
Hanna Kim¹, Kristina M. Brooks², Paul Wakim³, Mary Blake⁴, Stephen R. Brooks⁵, Gina A. Montealegre Sanchez⁶, Adriana Almeida de Jesus⁶, Yan Huang⁶, Wanxia Li Tsai⁷, Massimo G. Gadina⁴, Parag Kumar² and Raphaela Goldbach-Mansky⁶, ¹Pediatric Translational Research Branch, NIAMS/NIH, Bethesda, MD, ²Clinical Pharmacokinetics Research Unit, Pharmacy Department, NIH Clinical Center, Bethesda, MD, ³Biostatistics and Clinical Epidemiology Service, NIH Clinical Center, Bethesda, MD, ⁴Translational Immunology Section, Office of Science and Technology, NIAMS/NIH, Bethesda, MD, ⁵Biodata Mining and Discovery Section, Office of Science and Technology, NIAMS/NIH, Bethesda, MD, ⁶Translational Autoinflammatory Disease Studies (TADS), Laboratory of Clinical Investigation and Microbiology (LCIM), NIAID/NIH, Bethesda, MD, ⁷Translational Immunology, Office of Science and Technology, NIAMS/NIH, Bethesda, MD
Background/Purpose: JAK inhibitors reduce IFN-signaling ex vivo. We evaluated the PK and PD of the oral JAK1 and JAK2 inhibitor, baricitinib, from data collected in…
Abstract Number: 506 • 2017 ACR/ARHP Annual Meeting
The Selective JAK1 Inhibitor Upadacitinib Has No Effect on Pharmacokinetics of the Hormonal Contraceptives Levonorgestrel and Ethinylestradiol
Mohamed-Eslam F. Mohamed¹, Sheryl Trueman¹, Tian Feng², Alan Friedman³ and Ahmed A. Othman², ¹Clinical Pharmacology and Pharmacometrics, AbbVie, North Chicago, IL, ²AbbVie, North Chicago, IL, ³AbbVie Inc., North Chicago, IL
Background/Purpose: Upadacitinib is a selective JAK1 inhibitor being developed for the treatment of several inflammatory diseases, including rheumatoid arthritis (RA). Upadacitinib showed favorable efficacy and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].